Skip to main content
OpenTrials
Completed

NCT Number: NCT03787719

Dialysis-Less Frequently In The Elderly

Thrice-weekly dialysis is the accepted standard of care for hemodialysis (HD) patients. Observational studies suggest that elderly HD patients do as well and have better quality of life with less dialysis (ie twice-weekly). We propose a single-center pilot study of 40 patients to determine the feasibility of a large randomized controlled trial (RCT) designed to determine the impact of HD frequency on well-being in new HD patients above the age of 70. The primary outcomes will be metrics of feasibility and safety. We hypothesize that an adequately powered RCT that will determine whether elderly patients who dialyze twice weekly have improved well-being compared to thrice-weekly is feasible

Completed

Looking for future studies?

Notify Me

Key information

About this study

This single-center pilot study of 40 patients is designed to determine the feasibility and safety of a large randomized controlled trial examining the impact of hemodialysis frequency on well-being, a patient reported outcome, in incident patients with end stage kidney disease who are above the age of 70. Subjects meeting inclusion criteria will be enrolled into the trial if they are still alive 7 weeks post HD initiation. Once enrolled, subjects will continue thrice weekly HD, have weekly potassium measured, have intra-dialytic weight gain and dry weight assessed weekly and have any extra or missed HD sessions and death recorded. Six weeks post enrollment, subjects meeting inclusion for randomization (potassium within normal range on K2,3 or 4 bath and mean inter-dialytic weight gain of less than 2 L and within 1.0 kg of their prescribed dry weight on weeks 5 and 6) will have residual GFR measured by iohexol clearance and by the average of 48 hour urea and creatinine clearance. Randomization will be 1:1 using permuted blocks of undisclosed varying size and stratified by residual kidney function (RKF) (<5 ml/min, 5-10 ml/min and >10 ml/min) measured by the average of 48 hour urea and creatinine clearance. Throughout the remaining 9 months, potassium will be measured weekly, interdialytic weight gain recorded, and missed or extra HD sessions and death will be recorded. Every 6 weeks, ESAs-r and every 3 months the SF-36 will be completed. The primary outcome for this single-center pilot study will be metrics of feasibility and safety. Feasibility will be assessed by rate of enrollment into the trial and rate of subsequent randomization to a treatment arm, adherence to protocol and loss to trial completion. Safety will be assessed by measures of serum potassium and achievement of target weight. We hypothesize that an adequately powered RCT (The D-LITE Main Trial) that will determine whether elderly patients who dialyze twice weekly have better self-reported well-being compared to thrice weekly will be feasible.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Greater than equal 70 years old, planned ongoing in-center HD treatment
  • Incident HD patient and still alive 7 weeks post HD initiation
  • Patient or substitute decision maker provide informed consent

Exclusion criteria

  • Significant barriers to ascertainment of the patient-reported experience measures
  • Patient currently admitted to hospital without Alternate Level of Care designation
  • Patient non-adherent to dialysis prescription

Treatment and study plan

Twice per week dialysis

Other

Twice-weekly 4 hour dialysis treatment

Primary outcomes

  1. Recruitment

    Time frame: 1 year

    Successful recruitment will be defined as >3-4 patients/month over 12 months providing informed consent and meeting criteria for randomization.

  2. percent of prescribed treatments completed by patient

    Time frame: 1 year

    Successful adherence will be defined as => 90% of intervention being adhered to.

  3. Loss to trial completion

    Time frame: 1 year

    Successful loss to trial completion will be defined as = >50% of randomized patients completing the 12 month trial. Based on our data, the anticipated reasons for loss to trial completion will be death and moving away from the study center.

  4. Percent of weekly potassium values falling within normal range.

    Time frame: 1 year

    Potassium will be measured every week for the duration of the study.

  5. Percent of weekly post hemodialysis weights that are within 1 kg of prescribed dry weight

    Time frame: 1 year

    Prescribed and acheived post HD weight will be recorded weekly.

Secondary outcomes

  1. Change in Patient's Quality of Life - Using Edmonton Symptom Assessment System (ESAS-R)

    Time frame: 1 year

    The purpose of the ESAS tool is to help with the assessment of 9 symptoms which includes: pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, shortness of breath and well-being.

    The ESAS-R is a semantic differential scale which asks respondents to answer a questionnaire and choose between two opposite position (e.g., "No Pain" or "Worst Possible Pain", "No Tiredness" or "Worst Possible Tiredness", etc). The patient will rate the severity of each symptom from 0 to 10. The lower the value the better the outcome.

    This study will measure the change in ESAS-r symptoms over time. The ESAS-r is always done on the ESAS-r numerical scale and the results later transferred to the ESAS-r Graph.

Sponsors and collaborators

Lead sponsor

Dr. Christine White

Other

Registry information

Official study title

Dialysis-Less Frequently In The Elderly (D-LITE) Pilot Study

Acronym: D-LITE

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Dec 26, 2018
Registry last updated
May 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.